![]() ![]() You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Between 66-89% of retail investor accounts lose money when trading CFDs. Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. This keeps our service impartial and ad-free. Please open a trading account through our links to tip us. It does not constitute financial advice.Īffiliate links: This blog is supported by its readers. Information published on this website is factual and for information purposes only. is an online publication that covers Forex and CFD providers. We do not accept deposits, do not process payments, do not advise on investments, do not deal in investments (as agent or principal) and do not arrange deals in investments. Information published on this website is not directed at residents of the United Arab Emirates or Belgium and is not intended for use by any person in any jurisdiction where such use would be contrary to local law or regulation.ĭisclaimer: is not a Forex or a CFD provider. " The Top Medical Monitoring and Healthcare Wearable Device Trends of is a trademark of Media Vest FZ-LLC, a company incorporated with the Dubai Development Authority in the United Arab Emirates under registration number 101647. " New Survey: Virtual Care Could Keep Low-Acuity Cases Out of Emergency Department." " US Healthcare Industry in 2022: Analysis of the Health Sector, Healthcare Trends, and Future of Digital Health."īipartisan Policy Center. " Opportunities abound in health care stocks." " Merck to buy Prometheus Biosciences for about $11 billion."Ĭenters for Medicare and Medicaid Services. " Cabaletta Bio Announces CABA-201, a Newly Designed CD19 Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases." ![]() " Cabaletta Bio Receives FDA Fast Track Designation for CABA-201."Ĭabaletta Bio. " Viking joins obesity drug race after promising early trial data."Ĭabaletta Bio Inc. " Royalty Pharma Reports First Quarter 2023 Results."ĪstraZeneca PLC. " Q4 & FY23 Financial Results," Pages 1, 4, 5, 13. Quote Chart End-of-Day Trading Signals Intraday Alerts Profile Buy or Sell News Discussion. " Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results."ĭr Reddy's Laboratories Inc. Technical Analysis for JAZZ - Jazz Pharmaceuticals plc. " Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma." " Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Low P/S No Reason For Excitement." Nonetheless, EPS quadrupled on reductions in operating costs and foreign exchange benefits. AstraZeneca's revenue declined in the first quarter of 2023 as sales of its COVID-19 products fell. AstraZeneca PLC: AstraZeneca is a British-Swedish healthcare holding company that, through subsidiaries, researches, manufactures, and markets pharmaceutical products for gastrointestinal, central nervous system, and cardiovascular disorders, among others.Royalty's financial performance in the latest quarter was driven by momentum from the FDA's approval of Pfizer's migraine treatment Zavzpret, in which the company maintains a royalty interest. Royalty Pharma PLC: Royalty Pharma is a biopharmaceuticals royalties company that partners with companies to fund late-stage clinical trials and also purchases existing royalties for therapeutics.Particularly strong growth in both the company's India and North America segments contributed to significant EPS growth in the most recent quarter. Dr Reddy's Laboratories Ltd.: Dr Reddy's is an Indian pharmaceutical company that produces generics and biosimilars for gastrointestinal and cardiovascular disorders, pain management, and other therapeutic needs. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |